NASDAQ:ATHX Athersys Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.25 +0.01 (+4.21%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$0.24▼$0.2550-Day Range$0.18▼$0.7652-Week Range$0.18▼$1.81Volume2.44 million shsAverage Volume8.41 million shsMarket Capitalization$65.38 millionP/E RatioN/ADividend YieldN/APrice Target$0.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Athersys MarketRank™ ForecastAnalyst RatingReduce1.00 Rating ScoreUpside/Downside0.9% Upside$0.25 Price TargetShort InterestHealthy22.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.27) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.75 out of 5 starsMedical Sector1160th out of 1,433 stocksPharmaceutical Preparations Industry559th out of 683 stocks 0.5 Analyst's Opinion Consensus RatingAthersys has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.25, Athersys has a forecasted upside of 0.9% from its current price of $0.25.Amount of Analyst CoverageAthersys has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted22.86% of the float of Athersys has been sold short.Short Interest Ratio / Days to CoverAthersys has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Athersys has recently decreased by 16.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAthersys does not currently pay a dividend.Dividend GrowthAthersys does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHX. Previous Next 2.0 News and Social Media Coverage News SentimentAthersys has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Athersys this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Athersys to their MarketBeat watchlist in the last 30 days. This is a decrease of -26% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athersys insiders have not sold or bought any company stock.Percentage Held by Insiders10.50% of the stock of Athersys is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Athersys is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athersys are expected to grow in the coming year, from ($0.27) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athersys is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athersys is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthersys has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address About Athersys (NASDAQ:ATHX) StockAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.Read More ATHX Stock News HeadlinesJuly 6, 2022 | americanbankingnews.comAthersys, Inc. (NASDAQ:ATHX) Short Interest Down 16.7% in JuneJuly 5, 2022 | finance.yahoo.comThinking about buying stock in Cowen, OneConnect Financial Tech, Faraday Future Intelligent Electric, RA Medical Systems, or Athersys?July 3, 2022 | americanbankingnews.comAthersys (NASDAQ:ATHX) Coverage Initiated at StockNews.comJune 21, 2022 | businesswire.comAthersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures - Business WireJune 18, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)June 17, 2022 | bizjournals.comAthersys shares rebound somewhat since falling by two-thirds on clinical trial results - The Business JournalsJune 15, 2022 | finance.yahoo.comAthersys (NASDAQ:ATHX) adds US$19m to market cap in the past 7 days, though investors from three years ago are still down 79%June 9, 2022 | benzinga.comThinking about buying stock in DiDi Global, Rigel Pharmaceuticals, Annaly Capital Management, FuelCell Energy, or Athersys? - BenzingaJune 9, 2022 | seekingalpha.comATHX stock falls over proposal for reverse stock split (NASDAQ:ATHX) - Seeking AlphaJune 9, 2022 | streetinsider.comAthersys Postpones Annual Meeting of Stockholders - StreetInsider.comJune 8, 2022 | businesswire.comAthersys Hosting KOL Panel Event to Discuss TREASURE Data - Business WireJune 6, 2022 | streetinsider.comTop Penny Stocks To Buy For Under $1? 3 To Watch This Week - StreetInsider.comJune 3, 2022 | seekingalpha.comAthersys laying off 70% of workforce in wake of stroke study results (NASDAQ:ATHX) - Seeking AlphaJune 3, 2022 | bizjournals.comAthersys to cut up to 70% of its workers in effort to survive - The Business JournalsJune 2, 2022 | businesswire.comAthersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs - Business WireJune 2, 2022 | finance.yahoo.comAthersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs - Yahoo FinanceMay 23, 2022 | benzinga.comB of A Securities Downgrades Athersys to Underperform, Lowers Price Target to $0.25 - Benzinga - BenzingaMay 23, 2022 | seekingalpha.comAthersys stock slumps ~19% after Bank of America downgrade to Underperform - Seeking AlphaMay 23, 2022 | finance.yahoo.comAthersys (ATHX) Down as Ischemic Stroke Study Fails to Meet GoalMay 20, 2022 | benzinga.comAthersys shares are trading lower after the company announced that its partner, Healios, reported topline - BenzingaMay 20, 2022 | investing.comUS stocks mixed at close of trade; Dow Jones Industrial Average up 0.03% By Investing.com - Investing.comMay 20, 2022 | benzinga.comThinking about buying stock in Roblox Corp, Athersys, Plug Power, DiDi Global, or Zynga? - Benzinga - BenzingaMay 20, 2022 | businesswire.comAthersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study - Business WireMay 13, 2022 | benzinga.comAthersys to Participate in the H.C. Wainwright Global Investment Conference - Benzinga - BenzingaMay 13, 2022 | finance.yahoo.comAthersys to Participate in the H.C. Wainwright Global Investment ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHX CUSIPN/A CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees104Year Founded1995Company Calendar Last Earnings5/06/2022Today7/07/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$0.25 High Stock Price Forecast$0.25 Low Stock Price Forecast$0.25 Forecasted Upside/Downside+0.9%Consensus RatingReduce Rating Score (0-4)1 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,960,000.00 Net MarginsN/A Pretax Margin-981.52% Return on Equity-323.22% Return on Assets-120.69% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$5.51 million Price / Sales11.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book3.54Miscellaneous Outstanding Shares263,930,000Free Float225,511,000Market Cap$65.38 million OptionableOptionable Beta-1.29 Social Links Athersys Frequently Asked Questions Should I buy or sell Athersys stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" Athersys stock. View analyst ratings for Athersys or view top-rated stocks. What is Athersys' stock price forecast for 2022? 1 Wall Street analysts have issued 12 month price targets for Athersys' shares. Their ATHX stock forecasts range from $0.25 to $0.25. On average, they predict Athersys' stock price to reach $0.25 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price. View analysts' price targets for Athersys or view top-rated stocks among Wall Street analysts. How has Athersys' stock price performed in 2022? Athersys' stock was trading at $0.9026 at the start of the year. Since then, ATHX stock has decreased by 72.6% and is now trading at $0.2477. View the best growth stocks for 2022 here. When is Athersys' next earnings date? Athersys is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Athersys. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings results on Friday, May, 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $2.91 million for the quarter. View Athersys' earnings history. Who are Athersys' key executives? Athersys' management team includes the following people: Dr. John J. Harrington Ph.D., Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 55, Pay $706.67k) (LinkedIn Profile)Mr. Ivor Macleod CPA, M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 60, Pay $549.87k) (LinkedIn Profile)Mr. Daniel A. Camardo M.B.A., CEO & Director (Age 53)Ms. Karen Hunady M.S., Director of Corp. Communications & Investor RelationsMs. Alison O'Sullivan M.B.A., Sr. Director of HRDr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory AffairsDr. Robert Mays Ph.D., VP of Regenerative Medicine & Head of Neuroscience ProgramsMr. Rakesh Ramachandran, Head of Information Technology & Communications and VPMs. Maia Hansen M.B.A., M.S., Sr. VP and Head of Operations & Supply ChainDr. Eric Jenkins M.D., Sr. Medical Director & Head of Clinical Operations What is Gil Van Bokkelen's approval rating as Athersys' CEO? 2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Athersys' key competitors? Some companies that are related to Athersys include CymaBay Therapeutics (CBAY), Rallybio (RLYB), PepGen (PEPG), Thorne HealthTech (THRN), InterCure (INCR), Inventiva (IVA), Prelude Therapeutics (PRLD), Epizyme (EPZM), Sernova (SEOVF), KalVista Pharmaceuticals (KALV), AVEO Pharmaceuticals (AVEO), XOMA (XOMA), Aldeyra Therapeutics (ALDX), Rigel Pharmaceuticals (RIGL) and Viking Therapeutics (VKTX). View all of ATHX's competitors. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). What is Athersys' stock symbol? Athersys trades on the NASDAQ under the ticker symbol "ATHX." How do I buy shares of Athersys? Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Athersys' stock price today? One share of ATHX stock can currently be purchased for approximately $0.25. How much money does Athersys make? Athersys (NASDAQ:ATHX) has a market capitalization of $65.38 million and generates $5.51 million in revenue each year. The biopharmaceutical company earns $-86,960,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. How many employees does Athersys have? Athersys employs 104 workers across the globe. When was Athersys founded? Athersys was founded in 1995. How can I contact Athersys? Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for Athersys is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495. This page (NASDAQ:ATHX) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
